Mutant Hsp70 Protein Enhances Microautophagy in Motor Neurons
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for motor neuron diseases like spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) are limited, with a need for effective therapies that address the selective vulnerability of motor neurons and the underlying mechanisms of protein depletion.
Innovation Solution
Administration of a mutant Hsp70 family member protein, such as mutant Hspa8, or a modulator thereof, to enhance microautophagy activity and reduce chaperone activity, which can be delivered via nucleic acid molecules or viral vectors like AAV to the central nervous system, potentially offering a treatment for SMA and ALS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If SMN2 splicing is modified to increase full-length transcript levels, then SMN protein levels increase, but the selective vulnerability of motor neurons and disease mechanism remain unaddressed
Solution Approach 1:
The patent extracts and addresses the specific problem of motor neuron vulnerability by introducing a targeted approach using mutant Hsp70 proteins that specifically act on motor neurons. Rather than simply increasing SMN levels systemically, the invention introduces a separate therapeutic agent (mutant Hsp70) that specifically protects motor neurons from degeneration, thereby addressing the selective vulnerability issue that SMN2 splicing modification alone cannot resolve.
2Reliability
If Hsp70 chaperone activity is increased, then protein folding is improved, but microautophagy activity is reduced
Solution Approach 1:
The patent applies local quality by creating a mutant Hsp70 protein with non-uniform functional properties - the mutant form has specifically altered chaperone activity while retaining or enhancing microautophagy activity. This localized modification of protein function allows the therapeutic agent to provide differentiated effects: reduced chaperone activity to avoid interfering with normal protein folding while maintaining microautophagy activity to protect motor neurons from aggregate accumulation and degeneration.
3Ease of operation
If current treatments are used for SMA and ALS, then some symptomatic relief may be achieved, but effective disease-modifying therapy is lacking
Solution Approach 1:
The patent applies preliminary action by introducing a therapeutic mechanism that acts upstream of symptom manifestation - the mutant Hsp70 protein prevents motor neuron degeneration through enhanced microautophagy activity before clinical symptoms develop or progress. This preventive approach targets the underlying pathological mechanism (motor neuron vulnerability) rather than merely treating symptoms, thereby achieving disease modification rather than just symptomatic relief.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach results in increased microautophagy activity, preservation of motor neurons, and improvement in neuromuscular junction function, leading to extended lifespan and reduced disease severity in SMA models, suggesting a potential disease-modifying treatment for motor neuron diseases.
Implementation Method 1
Administration of a mutant Hsp70 family member protein, such as mutant Hspa8, or a modulator thereof, to enhance microautophagy activity
Implementation Method 2
which can be delivered via nucleic acid molecules or viral vectors like AAV to the central nervous system
Data Source
AI summary
The present disclosure provides compositions and methods of treating motor neuron diseases, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). A modulator of a heat shock protein, such as an Hsp70 family member protein, may be used in the present method. Alternatively, a mutant heat shock protein may be used.